MetLife Investment Management’s Avita Medical RCEL Stock Holding History

MetLife Investment Management’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,059	Closed	-$79.7K	–	2902
2025 Q2	$79.7K	Hold	15,059	–	–	﹤0.01%	2646
2025 Q1	$123K	Hold	15,059	–	–	﹤0.01%	2429
2024 Q4	$193K	Hold	15,059	–	–	﹤0.01%	2323
2024 Q3	$161K	Hold	15,059	–	–	﹤0.01%	2398
2024 Q2	$119K	Buy	15,059 +1,414	+10%	+$13.4K	﹤0.01%	2517
2024 Q1	$219K	Hold	13,645	–	–	﹤0.01%	2156
2023 Q4	$187K	Hold	13,645	–	–	﹤0.01%	2277
2023 Q3	$199K	Hold	13,645	–	–	﹤0.01%	2208
2023 Q2	$232K	Buy	+13,645	New	+$200K	﹤0.01%	2183
2022 Q1	–	Sell	-10,458	Closed	-$125K	–	2764
2021 Q4	$125K	Hold	10,458	–	–	﹤0.01%	2322
2021 Q3	$185K	Hold	10,458	–	–	﹤0.01%	2145
2021 Q2	$215K	Buy	+10,458	New	+$206K	﹤0.01%	2125

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

MetLife Investment Management's RCEL Position: Q3 2025 in Review

MetLife Investment Management sold out of Avita Medical (RCEL) in Q3 2025, closing a stake of 15,059 shares — an estimated $79.7K sold.

MetLife Investment Management first reported a position in RCEL in Q2 2021 and held it in 12 quarters. The position peaked at $232K in Q2 2023. 76 funds tracked by Wall St. Rank hold RCEL as of Q3 2025.

MetLife Investment Management reported no remaining Avita Medical position as of Q3 2025 after selling out during the quarter.
MetLife Investment Management sold 15,059 Avita Medical shares in Q3 2025, an estimated $79.7K.
MetLife Investment Management first reported a position in Avita Medical in Q2 2021 and held it in 12 quarters.
MetLife Investment Management's Avita Medical position peaked at $232K in Q2 2023.
76 funds tracked by Wall St. Rank held Avita Medical as of Q3 2025.

Based on MetLife Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.